Crude OR (95% CI) | Age adjusted OR/HR (95% CI) | Multivariable adjusted OR/HR* (95% CI) | |
---|---|---|---|
Men, MDRD (N=23 313) | |||
In-hospital mortality | |||
Per 10 mL/min decline | 1.52 (1.48 to 1.56) | 1.35 (1.31 to 1.39) | 1.33 (1.18 to 1.28) |
CKD compared with non-CKD | 6.73 (5.96 to 7.60) | 3.41 (2.99 to 3.89) | 2.59 (2.19 to 3.07) |
CKD stage 1 (n=7623) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
CKD stage 2 (n=11 277) | 2.25 (1.82 to 2.77) | 1.50 (1.21 to 1.85) | 1.38 (1.07 to 1.77) |
CKD stage 3 (n=3797) | 9.50 (7.73 to 11.68) | 3.79 (3.04 to 4.72) | 2.76 (2.12 to 3.60) |
CKD stage 4–5 (n=612) | 28.92 (22.50 to 37.17) | 11.30 (8.66 to 14.75) | 7.23 (5.18 to 10.09) |
Long-term mortality | |||
Per 10 mL/min decline | 1.36 (1.34 to 1.38) | 1.19 (1.18 to 1.21) | 1.09 (1.07 to 1.11) |
CKD compared with non-CKD | 4.29 (4.06 to 4.55) | 2.16 (2.02 to 2.30) | 1.57 (1.43 to 1.72) |
CKD stage 1 (n=7623) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
CKD stage 2 (n=11 277) | 1.63 (1.50 to 1.78) | 1.07 (0.98 to 1.17) | 1.09 (0.97 to 1.22) |
CKD stage 3 (n=3797) | 5.19 (4.75 to 5.67) | 1.99 (1.81 to 2.19) | 1.56 (1.37 to 1.77) |
CKD stage 4–5 (n=612) | 13.27 (11.76 to 14.97) | 5.03 (4.43 to 5.71) | 2.55 (2.12 to 3.06) |
Women, MDRD (N=12 039) | |||
In-hospital mortality | |||
Per 10 mL/min decline | 1.42 (1.38 to 1.46) | 1.29 (1.25 to 1.33) | 1.28 (1.23 to 1.33) |
CKD compared with non-CKD | 4.24 (3.73 to 4.82) | 2.57 (2.25 to 2.94) | 2.01 (1.69 to 2.38) |
CKD stage 1 (n=2400) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
CKD stage 2 (n=5054) | 1.76 (1.37 to 2.26) | 1.22 (0.94 to 1.57) | 1.25 (0.93 to 1.71) |
CKD stage 3 (n=3887) | 5.14 (4.06 to 6.52) | 2.42 (1.89 to 3.10) | 1.96 (1.45 to 2.66) |
CKD stage 4–5 (n=697) | 15.83 (12.10 to 20.72) | 7.31 (5.52 to 9.68) | 5.62 (3.95 to 8.00) |
Long-term mortality | |||
Per 10 mL/min decline | 1.33 (1.31 to 1.35) | 1.20 (1.18 to 1.22) | 1.11 (1.09 to 1.14) |
CKD compared with non-CKD | 3.10 (2.91 to 3.31) | 1.87 (1.75 to 2.01) | 1.47 (1.34 to 1.62) |
CKD stage 1 (n=2400) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
CKD stage 2 (n=5054) | 1.44 (1.28 to 1.62) | 0.99 (0.88 to 1.11) | 1.05 (0.89 to 1.23) |
CKD stage 3 (n=3887) | 3.47 (3.10 to 3.88) | 1.61 (1.44 to 1.81) | 1.37 (1.17 to 1.61) |
CKD stage 4–5 (n=697) | 9.22 (8.08 to 10.54) | 4.10 (3.57 to 4.70) | 2.79 (2.30 to 3.39) |
Men, CG (N=17 792) | |||
In-hospital mortality | |||
Per 10 mL/min decline | 1.51 (1.46 to 1.56) | 1.36 (1.31 to 1.42) | 1.29 (1.23 to 1.36) |
CKD compared with non-CKD | 7.92 (6.71 to 9.35) | 3.15 (2.56 to 3.89) | 2.49 (1.95 to 3.17) |
CKD stage 1 (n=7940) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
CKD stage 2 (n=5962) | 2.86 (2.15 to 3.80) | 1.61 (1.19 to 2.19) | 1.48 (1.05 to 2.08) |
CKD stage 3 (n=3363) | 11.29 (8.70 to 14.66) | 3.91 (2.81 to 5.42) | 2.97 (2.05 to 4.31) |
CKD stage 4–5 (n=521) | 36.47 (26.83 to 49.57) | 11.47 (7.86 to 16.74) | 7.07 (4.55 to 10.99) |
Long-term mortality | |||
Per 10 mL/min decline | 1.41 (1.39 to 1.43) | 1.21 (1.19 to 1.24) | 1.11 (1.08 to 1.13) |
CKD compared with non-CKD | 5.43 (5.04 to 5.84) | 2.00 (1.82 to 2.19) | 1.43 (1.27 to 1.60) |
CKD stage 1 (n=7940) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
CKD stage 2 (n=5962) | 2.32 (2.07 to 2.60) | 1.16 (1.02 to 1.32) | 1.18 (1.01 to 1.37) |
CKD stage 3 (n=3363) | 7.20 (6.47 to 8.01) | 2.00 (1.74 to 2.30) | 1.53 (1.29 to 1.82) |
CKD stage 4–5 (n=521) | 22.75 (19.81 to 26.12) | 5.64 (4.75 to 6.70) | 2.60 (2.09 to 3.24) |
Women, CG (N=8794) | |||
In-hospital mortality | |||
Per 10 mL/min decline | 1.47 (1.41 to 1.53) | 1.29 (1.23 to 1.36) | 1.22 (1.14 to 1.30) |
CKD compared with non-CKD | 5.52 (4.46 to 6.84) | 2.28 (1.78 to 2.92) | 1.87 (1.40 to 2.49) |
CKD stage 1 (n=1675) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
CKD stage 2 (n=2731) | 2.25 (1.41 to 3.59) | 1.26 (0.78 to 2.04) | 1.32 (0.73 to 2.36) |
CKD stage 3 (n=3485) | 7.42 (4.85 to 11.39) | 2.47 (1.54 to 3.96) | 2.09 (1.17 to 3.73) |
CKD stage 4–5 (n=900) | 20.38 (13.12 to 31.66) | 5.23 (3.15 to 8.70) | 3.51 (1.87 to 6.56) |
Long-term mortality | |||
Per 10 mL/min decline | 1.43 (1.40 to 1.46) | 1.26 (1.23 to 1.30) | 1.16 (1.12 to 1.19) |
CKD compared with non-CKD | 4.55 (4.11 to 5.04) | 2.00 (1.78 to 2.25) | 1.71 (1.47 to 1.99) |
CKD stage 1 (n=1675) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
CKD stage 2 (n=2731) | 1.93 (1.57 to 2.38) | 1.14 (0.92 to 1.41) | 1.38 (1.05 to 1.82) |
CKD stage 3 (n=3485) | 5.71 (4.72 to 6.92) | 2.04 (1.64 to 2.53) | 2.17 (1.64 to 2.87) |
CKD stage 4–5 (n=900) | 15.41 (12.62 to 18.82) | 4.26 (3.37 to 5.39) | 3.03 (2.23 to 4.11) |
*Adjusted for age, smoking, diabetes, hypertension, previous MI, previous PCI, previous CABG, chronic heart failure, previous stroke, chronic obstructive pulmonary disease, dementia, peripheral artery disease, previous cancer and therapy on arrival, and, regarding long-term mortality analyses, also therapy at discharge.
CABG, coronary artery bypass grafting; CG, Cockcroft-Gault; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease study formula; MI, myocardial infarction; PCI, percutaneous coronary intervention.